This report was first published by Endpoints News. To see the original version, click here
Bain Capital is implementing a blueprint that’s worked before, officially launching a company Wednesday with five assets from Bristol Myers Squibb.
The biotech will be called Beeline Medicines and will officially get things going with programs in lupus, eczema, plaque psoriasis and other inflammatory diseases. The company will be led by Saqib Islam, formerly the CEO of SpringWorks Therapeutics, a 2017 Pfizer spinout backed by Bain Capital Life Sciences that focused on rare cancer drugs.
您已阅读15%（580字），剩余85%（3254字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。